Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates.
Our vision is to significantly change the practice of oncology by developing medicines that provide truly meaningful improvements in quality of life and survival for people with cancer. Our wholly-owned pipeline includes differentiated and novel oncology therapeutic candidates that have been generated from our drug discovery and developmental programs. We were founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.